Naproxen Should Be NSAID Trial Standard, FDA And Committees Say
This article was originally published in The Pink Sheet Daily
Executive Summary
The agent is excluded from non-steroidal anti-inflammatory drug cardiovascular warnings unanimously recommended by FDA advisory committees reviewing COX-2 inhibitors. FDA’s Temple says naproxen’s safety profile makes the drug suitable as a “reference standard” for the NSAID class.